NovaBay Pharmaceuticals, Inc. EBITDA Margin

EBITDA Margin of NBY for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBITDA Margin growth rates and interactive chart.


Highlights and Quick Summary

  • EBITDA Margin for the quarter ending September 30, 2022 was -8.83% (a -86.77% decrease compared to previous quarter)
  • Year-over-year quarterly EBITDA Margin decreased by -92.49%
  • Annual EBITDA Margin for 2021 was -103.82% (a 61.81% increase from previous year)
  • Annual EBITDA Margin for 2020 was -64.16% (a -53.86% decrease from previous year)
  • Annual EBITDA Margin for 2019 was -139.04% (a 128.68% increase from previous year)
  • Twelve month EBITDA Margin ending September 30, 2022 was -63.73% (a -33.11% decrease compared to previous quarter)
  • Twelve month trailing EBITDA Margin decreased by -38.61% year-over-year
Trailing EBITDA Margin for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
-63.73% -95.28% -102.69% -103.81%
Visit stockrow.com/NBY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBITDA Margin of NovaBay Pharmaceuticals, Inc.

Most recent EBITDA Marginof NBY including historical data for past 10 years.

Interactive Chart of EBITDA Margin of NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. EBITDA Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -8.83% -66.73% -86.0%
2021 -117.64% -123.7% -86.64% -83.62% -103.82%
2020 -92.53% -94.47% -26.53% -80.39% -64.16%
2019 -130.46% -122.17% -60.65% -271.9% -139.04%
2018 -43.14% -54.65% -71.47% -78.96% -60.8%
2017 6.86% -52.58% -42.19% -101.57% -39.58%
2016 -49.4% -59.05% -83.1% -268.24% -91.35%
2015 -380.92% -442.25% -477.98% -858.74% -478.73%
2014 -989.82% -2676.97% -3020.33% -1398.61% -1581.78%
2013 -939.8% -264.15% -479.95% -333.92% -436.35%
2012 -247.58% -0.66% -320.55% -181.36% -114.7%
2011 -192.2% -35.36%

Business Profile of NovaBay Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology